Bullfrog ai holdings, inc.
BFRG 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
BFRG 近期報酬表現
-0.96%
Bullfrog ai holdings, inc.
1.19%
同產業平均
0.91%
S&P500
與 BFRG 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TIL | Instil bio inc | 2 分 | 4 分 | 4 分 | 2 分 | 1 分 | |
CVKD | Cadrenal therapeutics inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
PDSB | Pds biotechnology corp | 3 分 | 3 分 | 3 分 | 1 分 | 1 分 | |
CRL | Charles river laboratories international inc | 5 分 | 2 分 | 1 分 | 3 分 | 1 分 | |
TBPH | Theravance biopharma inc | 3 分 | 2 分 | 1 分 | 2 分 | 1 分 |
- TIL Instil bio inc價值 2 分趨勢 4 分波段 4 分籌碼 2 分股利 1 分查看更多
BFRG 公司資訊
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence / machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company's platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.